Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine

Drug Metabolism Letters

Volumn 2, Issue 2, 2008, Pages 100-114

  Cashman, John R ^a,c   Zhang, Jun ^a   Nelson, Matthew R ^b   Braun, Andreas ^b  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b SEQUENOM INC   (United States)

^c NONE   (United States)

Author keywords

Delusions; Ethnic groups; Flavin containing monooxygenase 3; Hallucinations; Olanzapine; Pharmacogenetics; Schizophrenia; Side effects

Indexed keywords

DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 3; OLANZAPINE;

AFRICAN AMERICAN; AGE; ARTICLE; ASIAN AMERICAN; AUDITORY HALLUCINATION; CASE CONTROL STUDY; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DROWSINESS; DRUG CLEARANCE; DRUG METABOLISM; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISPANIC; HUMAN; HUMAN CELL; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POPULATION GENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN; WESTERN BLOTTING;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEX FACTORS;

EID: 47249112182     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231208784040942     Document Type: Article

References (32)

1. Rosenheck, R.A.; Leslie, D.L.; Sindelar, J.; Miller, E.A.; Lin, H.; Stroup, T.S.; McEvoy, J.; Davis, S.M.; Keefe, R.S.; Swartz, M.; Perkins, D.O.; Hsiao, J.K.; Lieberman, J.; CATIE Study Investigators. Am. J. Psychiatry, 2006, 163(12), 2080-2089.
2. Davis, J.M.; Chen, N.; Glick, I.D. Arch. Gen. Psychiatry, 2003, 60, 553-564.
3. Purdon, S.E.; Jones, B.; Stip, E.; Labelle, A.; Addington, D.; David, S.R.; Breier, A.; Tollefson, G.D. Arch. Gen. Psychiat., 2000, 57(3), 249-258.
4. Pae, C.U.; Ghaemi, S.; Patkar, A.; Chae, J.H.; Bahk, W.M.; Jun, T.Y.; Masand, P. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(7), 1322-1325.
5. Volavka, J.; Czobor, P.; Sheitman, B.; Lindenmayer, J.P.; Citrome, L.; McEvoy, J.P.; Cooper, T.B., Chakos, M,; Lieberman, J.A. Am. J. Psychiatry, 2002, 159(2), 255-262.
6. Gentile, S. Drug Saf., 2006, 29, 303-319.
7. Rubio, G.; Gomez-de-la-Camara, A.; Ledesma, F.; Baron, J.A.; Rodriguez-Morales, A.; Marinez-Junquera, G. Med. Clin., 2006, 126, 441-444.
8. Ozcanli, T.; Erdogan, A.; Ozdemir, S.; Onen, B.; Ozmen, M.; Doksat, K.; Sonsuz, A.; Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(6), 1163-1166.
9. Tyson, R.J.; Laws, K.R.; Flowers, K.A.; Tyson, A.; Mortimer, A.M. Psychiatry Clin. Neurosci., 2006, 473-479.
10. Lane, H.Y.: Liu, Y.C.; Huang, C.L.; Chang, Y.C.; Wu, P.L.; Lu, C.T.; Chang, W.H. J. Clin. Psychopharmacol., 2006, 26, 128-134.
11. Cholerton, S.; Daly, A.K.; Idle, J.R. Trends Pharmacol. Sci., 1992, 13, 434-442
12. Ring, B.J.; Catlow, J.; Lindsay, T.J.; Gillespie, T.; Roskos, L.K.; Cerimele, B.J.; Swanson, S.P.; Hamman, M.A.; Wrighton, S.A. J. Pharmacol. Exper. Therap., 1996, 276, 658-666.
13. Guengerich, F.P. (2005) in Human cytochromes P450 enzymes, (Ortiz de Monttellano, Ed.), Kluwer Academic/Plenum Publishers, New York, pp. 377-530.
14. Cashman, J.R.; Zhang, J. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 65-100.
15. Cashman, J.R. Pharmacogenomics, 2002, 3, 325-339.
16. Cashman, J.R; Zang, J. Drug Metab. Dispos., 2002, 30, 1043-1052.
17. Lattard, V.; Zhang, J.; Tran, Q.; Fumes, B.; Schlenk, D.; Cashman, J.R. Drug Metab. Dispos., 2003, 31, 854-860.
18. Mah, S.; Nelson, M.R.; DeLisi, L.E.; Reneland, R.H.; Markward, N.; James, M.R.; Nyholt, D.R.; Hayward, N.; Handoko, H.; Mowry, B.; Braun, A. Mol. Psychiatry. 2006, 11, 471-478.
19. DeLisi, L.E.; Shaw, S.H.; Grow, T.J.; Shields, G.; Smith, A.B.; Larach, V.W.; Wellman, N.; Loftus, J.; Nanthakumar, B.; Razi, K.; Stewart, J.; Comazzi, M.; Vita, A.; Heffner, T.; Sherrington, R. Am. J. Psychiatry, 2002, 159, 803-812.
20. Cashman, J.R.; Zhang, J.; Leuschner, J.: Braun, A. Drug Metab. Dispos., 2001, 29, 1629-1637.
21. Brunelle, A.; Bi, Y.A.; Lin, J.; Russeli B.; Lu, Y.C.; Berkman, C.E.; Cashman, J.R. Drug Metab. Dispos., 1997, 25, 1001-1007.
22. Lattard, V.; Zhang, J.; Cashman, J.R. Mol. Pharmacol., 2004, 65(6), 1525-1525.
23. Laemmli, U.K. Nature (Lond), 1970, 227, 680-685.
24. Towbin, E.P.; Staeheli, T.; Gordon, J. Proc. Natl. Acad. Sci. USA, 1979, 76, 435-4354.
25. Sachse, C.; Ruschen, S.; Dettling, M.; Schley, J.; Bauer, S.; Muller-Oerlinghausen, B.; Roots, I.; Brockmoller, J. Clin. Pharmacol. Ther., 1999, 66(4), 431-438.
26. Murray, M. J. Pharm. Pharmacol,, 2006, 58(7), 871-885.
27. Hamelin, B.A.; Dorson, P.G.; Pabis, D.; Still, D.; Bouchard, R.H.; Pourcher, E.; Rail, J.; Turgeon, J.; Crismon M.L. Pharmacotherapy, 1999, 19(9), 1057-1063.
28. Scordo, M.G.; Spina, E.; Romeo, P.; Dahl, M.L.; Bertilsson, L.; Johansson, I.; Sjoqvist, F. Eur. J. Clin. Phamacol., 2000, 56(9-10), 679-683.
29. Carrillo, J.A.; Herraiz, A.G.; Ramos, S.I.; Gervasini, G.; Vizcaino, S.; Benitez, J. J. Clin. Psychopharmacol., 2003, 23(2), 119-127.
30. Hagg, S.; Spigset, O.; Lakso, H.A.; Dahlqvist, R. Eur. J. Clin. Pharmacol., 2001, 57(6-7), 493-497.
31. Callaghan, J.T.; Bergstrom, R.F.; Ptak, L.R.; Beasley, C.M. Clin. Pharmacokinet., 1999, 37(3), 177-193.
32. Dahl, M.L. Clin. Pharmacokinet., 2002, 41(7), 453-470.